| Polio Eradication: Status, Struggles and Strategies AS Bandyopadhyay, RM Burke, KM Hawes The Pediatric Infectious Disease Journal 43 (6), e207-e211, 2024 | | 2024 |
| Nasal and pharyngeal mucosal immunity to poliovirus in children following routine immunization with inactivated polio vaccine (IPV) in the United States of America A Godin, RI Connor, HN Degefu, PC Rosato, WF Wieland-Alter, ... The Journal of Infectious Diseases, jiae264, 2024 | | 2024 |
| Use of inactivated poliovirus vaccine for poliovirus outbreak response AS Bandyopadhyay, RL Cavestany, IM Blake, G Macklin, L Cooper, ... The Lancet Infectious Diseases 24 (5), e328-e342, 2024 | 8 | 2024 |
| Novel oral polio vaccine type 2 use for polio outbreak response: A global effort for a global health emergency FD Kurji, AS Bandyopadhyay, S Zipursky, LV Cooper, C Gast, M Toher, ... Pathogens 13 (4), 273, 2024 | 1 | 2024 |
| Impact of supplementary immunization activities using novel oral polio vaccine type 2 during a large outbreak of circulating vaccine-derived poliovirus in Nigeria A Voorman, H Lyons, F Shuaib, US Adamu, C Korir, T Erbeto, ... The Journal of Infectious Diseases 229 (3), 805-812, 2024 | 1 | 2024 |
| Safety and immunogenicity of shorter interval schedules of the novel oral poliovirus vaccine type 2 in infants: a phase 3, randomised, controlled, non-inferiority study in the … LR Mejía, LP Méndez, AS Bandyopadhyay, C Gast, S Mazara, ... The Lancet Infectious Diseases 24 (3), 275-284, 2024 | 3 | 2024 |
| One billion doses and WHO prequalification of nOPV2: Implications for the global polio situation and beyond AS Bandyopadhyay, LV Cooper, S Zipursky PLOS Global Public Health 4 (2), e0002920, 2024 | 6 | 2024 |
| Effectiveness of poliovirus vaccines against circulating vaccine-derived type 2 poliomyelitis in Nigeria between 2017 and 2022: a case-control study LV Cooper, TB Erbeto, AA Danzomo, HW Abdullahi, K Boateng, ... The Lancet Infectious Diseases, 2024 | 8 | 2024 |
| Correction to Lancet Infect Dis 2023; published online Nov 24. https://doi. org/10.1016/S1473-3099 (23) 00505-4 AS Bandyopadhyay, R Lopez Cavestany, IM Blake | | 2023 |
| nOPV2 development as a global effort for polio outbreak response AS Bandyopadhyay, S Zipursky The Lancet Global Health 11 (11), e1695, 2023 | 2 | 2023 |
| The Origins and Risk Factors for Serotype-2 Vaccine-Derived Poliovirus Emergences in Africa During 2016–2019 EJ Gray, LV Cooper, AS Bandyopadhyay, IM Blake, NC Grassly The Journal of Infectious Diseases 228 (1), 80-88, 2023 | 7 | 2023 |
| Evaluation of novel oral polio vaccine type 2 SIA impact in a large outbreak of circulating vaccine-derived poliovirus in Nigeria. A Voorman, H Lyons, F Shuab, US Adamu, C Korir, T Erbeto, ... The Journal of Infectious Diseases, jiad222-jiad222, 2023 | 4 | 2023 |
| Enabling accelerated vaccine roll-out for public health emergencies of international concern (PHEICs): novel oral polio vaccine type 2 (nOPV2) experience GR Macklin, C Peak, M Eisenhawer, F Kurji, O Mach, J Konz, C Gast, ... Vaccine 41, A122-A127, 2023 | 37 | 2023 |
| Modelling the spread of serotype-2 vaccine derived-poliovirus outbreak in Pakistan and Afghanistan to inform outbreak control strategies in the context of the COVID-19 pandemic NA Molodecky, H Jafari, RM Safdar, JA Ahmed, A Mahamud, ... Vaccine 41, A93-A104, 2023 | 11 | 2023 |
| A novel tool to eradicate an ancient scourge: the novel oral polio vaccine type 2 story AS Bandyopadhyay, S Zipursky The Lancet Infectious Diseases 23 (2), e67-e71, 2023 | 30 | 2023 |
| Evaluation of the safety, immunogenicity, and faecal shedding of novel oral polio vaccine type 2 in healthy newborn infants in Bangladesh: a randomised, controlled, phase 2 … K Zaman, AS Bandyopadhyay, M Hoque, C Gast, M Yunus, KM Jamil, ... The Lancet 401 (10371), 131-139, 2023 | 15 | 2023 |
| Polio eradication: addressing the hurdles on the last mile KM Thompson, AS Lauring, AJ Pollard, R Andino, AS Bandyopadhyay, ... Cell 186 (1), 1-4, 2023 | 5 | 2023 |
| Genetic and phenotypic stability of poliovirus shed from infants who received novel type 2 or Sabin type 2 oral poliovirus vaccines in Panama: an analysis of two clinical trials R Wahid, LD Mercer, T De Leon, R DeAntonio, X Sáez-Llorens, ... The Lancet Microbe 3 (12), e912-e921, 2022 | 11 | 2022 |
| Economics of Eradication: Counting on the Polio Experience AS Bandyopadhyay, WA Orenstein The Journal of Infectious Diseases 226 (8), 1301-1303, 2022 | 1 | 2022 |
| Emergence of vaccine-derived poliovirus in high-income settings in the absence of oral polio vaccine use M Hill, AS Bandyopadhyay, AJ Pollard The Lancet 400 (10354), 713-715, 2022 | 34 | 2022 |
